0.00Open0.00Pre Close0 Volume0 Open Interest0.50Strike Price0.00Turnover0.00%IV-81.20%PremiumMay 16, 2025Expiry Date2.16Intrinsic Value100Multiplier5DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.80Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Cardiff Oncology Stock Discussion
Cardiff Oncology Announces a Second Patent for the Treatment of Mcrc for Bev-Naïve Patients
Major Progress: First-line Colorectal Cancer Treatment Trial Hits Key Milestone
Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal Cancer
Tuesday, 15th April at 4:05 pm
- Initial results from randomized Phase 2 CRDF-004 trial in RAS-mut mCRC were released in December 2024 -
- Additional clinical data from CRDF-004 trial expected in 1H 2025 -
SAN DIEGO, April 15, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ: CRDF), a c...
$SoFi Technologies (SOFI.US)$ $Palantir (PLTR.US)$ $Rockwell Automation (ROK.US)$
No comment yet